ABSTRACT
INTRODUCTION
OVARIAN cancer is considered the second highest incidence in gynecological cancers, ranks first in gynecologic cancer-related mortality, and is the fifth leading cause of cancer death among women world-wide (1) . If ovarian cancer is detected early, more than 93% of patients survive ≥ 5 years; however, more than 75% of cases are diagnosed at advanced stages with a poor prognosis for survival (American Cancer Society) (1) . Most ovarian cancers are believed to arise from the ovarian surface epithelium (OSE), a modified peritoneal mesothelium derived embryologically from the coelomic epithelium.
Characterizing the pathways that regulate the growth of OSE cells is a necessary first step toward understanding the events that lead to uncontrolled cellular proliferation and the development of ovarian cancer (1) . There appears to be a decreased risk of ovarian neoplasia with circumstances that decrease ovulatory frequency such as increased parity, breast feeding, and oral contraceptive use, whereas some studies seem to show an increased risk with the use of infertility drugs, although this finding remains controversial. These epidemiological findings suggest that suppression of folliculogenesis may be an important factor in decreasing the risk of epithelial ovarian cancer.
(2)
Human OSE cells express many of the receptors for hormones and growth factors produced by the ovarian surface epithelial, follicular, and stromal cells, leading to the suggestion that epithelial cell activity may be modified by autocrine and paracrine signals (1) . Activin A is a dimeric protein member of the transforming growth factor beta (TGFß) superfamily (3, 4) composed of two ß-subunits, ßA-ßA (activin A), ßB-ßB (activin B), or ßA-ßB (activin AB) (5) . It is synthesized by a variety of organs including normal endometrium. Activin A acts as an important regulator of cell growth and differentiation (4) . Activin was originally identified as an inducer for follicle-stimulating hormone (FSH) from the pituitary, and it has a central role in the regulation of the reproductive axis (6) . Follistatin is a soluble secreted glycoprotein that suppresses the release of FSH by binding to Activin and inhibiting its interaction with Activin receptors (7) . However, as Activin is produced locally in the ovary, it has been hypothesized that it may act via an autocrine/paracrine mechanism to regulate ovarian function (5) . Activin mediates its cellular effects through heterodimeric complexes of type I and II Activin serine/threonine kinase receptors. The importance of the Activin in regulating cell proliferation and possibly ovarian tumor development has been suggested by Fukuda et al; in 1998 (8) . To transmit the signal intracellularly, type I receptors activate a member of the SMAD family, which then translocates to the nucleus. Based on structural and functional characteristics, the Smad family is divided into three distinct classes: receptor-regulated Smads (R-Smads), common-mediator Smads (CoSmads), and inhibitory Smads (ISmads). R-Smads include Smad2 and 3, which are specifically recognized by activin and TGFß type I receptors, and Smad1, 5, and 8, which are used by bone morphogenetic proteins (BMP) receptors (9) . Receptor-regulated Smads, become phosphorylated by activated type I receptors and form heteromeric complexes with a common-partner Smad4, which translocates into the nucleus to control gene transcription. In addition to these signal transducing Smads, inhibitory Smads have been identified that inhibit the activation of receptor-regulated Smads.
( FS is a single-chain polypeptide with a structure unlike activin or inhibin. Alternative splicing events, proteolytic cleavage and variable glycosylation lead to a vast array of possible FS isoforms found within various biological fluids.
(16) FS in the circulation is most likely full-length FS 315 whereas FS in follicular fluid is predominately processed. Nearly all FS in circulation is bound to activin, and FS most likely acts as an autocrine/paracrine rather than endocrine factor in a number of tissues to regulate activin and other TGFß superfamily members. uPA has been associated with disease outcome as statistically independent prognostic markers in breast, lung, colon, kidney, and gastrointestinal cancers.
(28) Thus uPA could have a role in the pathogenesis of ovarian cancer progression.
The aim of the present study is to evaluate the potential clinical implication of circulating Activin A, follistatin, bikunin, endometrial tissue uPA and Smad-2 expression for diagnosis and progression of ovarian cancer. Total RNA were obtained from fresh-frozen ovarian tissues during surgery from all patients (33). Total cytoplasmic RNA for RT-PCR was isolated from ovarian cancer tissue using the single-step guanidinium isothiocyanate method (1) . Complementary DNA (cDNA) was synthesized from 10 µg of total cellular RNA by reverse transcription with Moloney murine leukemia virus reverse transcriptase (Life Technologies, Inc.) using random hexamers as primers (33) . RT-PCR was used to detect expression of smad2 target gene (30 cycles: 35 sec at 94 C, 35 sec at 59.5 C, 35 sec at 72 C) (1) .The Smad2 sense and antisense primers were used. The PCR mixture contained 50 mM Tris (pH 9.0), 50 mM KCl, 1.5 mM MgCl 2 , 0.01% gelatin, 100 ng of each primer, and 1 unit Taq polymerase (Life Technologies, Inc.). After an initial denaturation at 94°C for 5 min, amplification was carried out for 30 cycles at 94°C for 30 s, 55°C for 1 min, and 72°C for 1 min, followed by a final elongation step at 94°C for 2 min, 55°C for 2 min, and 72°C for 10 min. The PCR products were electrophoresed on a 2% agarose gel and stained with ethidium bromide.
SUBJECTS & METHODS
(1)
STATISTICS:
The values of the measured parameters were expressed as mean ± SD. The difference between groups was determined using ANOVA test (F-test). Pearson's correlation coefficient was performed for detection of the possible relation between the laboratory and biochemical variables. P<0.05 values were considered significant. All statistical analyses were processed using SPSS for windows, version 8.0. 0.0001* * significant at p< 0.05: significantly lower in group 1 and group 2 than in controls and than group 3, and also plasma bikunin levels were found to be significantly lower in group 3 than in controls. The levels of Activin A were found to be significantly higher in serous ovarian carcinoma than in ovarian cystadenoma and controls. Levels of Activin A were significantly higher in mucinous ovarian carcinoma than all other groups, including serous ovarian carcinoma. Also levels of Activin were significantly higher in serous ovarian cystadenoma than controls. (F= 299.73, p = 0.0001) ( Table 2 ).
RESULTS
In the present study, levels of serum Follistatin were found to be significantly higher in serous ovarian carcinoma than in ovarian cystadenoma and controls (pre-and postmenopausal). Levels of Follistatin were significantly higher in mucinous ovarian carcinoma than all other groups, including serous ovarian carcinoma. Also levels of Follistatin were significantly higher in serous ovarian cystadenoma than controls. (F= 54.75, p = 0.0001) ( Table 3) Plasma levels of Bikunin were found to be significantly lower in patients with serous ovarian carcinoma (Group 1) and mucinous ovarian carcinoma (group 2) than in controls (group 4 and 5) and than patients with ovarian cystadenoma, and also serum Bikunin levels were found to be significantly lower in ovarian cystadenoma than in controls. (F=231.22, p =0.0001) ( Table 4) .
In the present study, levels of uPA in ovarian tissue were significantly higher in serous and mucinous ovarian carcinoma than in ovarian cystadenoma and controls (pre-and postmenopausal). Also levels of uPA were significantly higher in ovarian carcinoma with metastases than those without metastases. Levels of uPA were found to be increased with progression of the stage of ovarian tumor. (F= 338.86, p = 0.001) ( Table 5) .
On performing correlation studies between the studied parameters, direct positive correlation was found between Activin and Follistatin (correlation co-efficient (r = 0.87, p < 0.001). Also a significant negative correlation was detected between Activin and Bikunin (correlation coefficient (r = -0.92, p < 0.001), and between Follistatin and Bikunin (correlation co-efficient (r = -0.86, p < 0.001). Finally, uPA was found to be significantly positively correlated with activin A, Follistatin (r = 0.96, 0.93, respectively at p < 0.01) and inversely correlated with bikunin (r = -0.95 at p < 0.01) ( Table 6 ).
Results of Smad-2 mRNA by RT-PCR (Figure 1)
Total RNA obtained from ovarian tumors (serous, mucinous ovarian carcinoma and cystadenoma) was reverse transcribed as described in "Methods." The resulting cDNA was PCR-amplified using primers specific for Smad2. Positive control (+), plasmids encoding the cDNA for Smad2; negative control (-), water. Figure (1) shows the result of RT-PCR of 10 ovarian tumors which highly expressed Smad-2. Smad-2 expression was found in 75% of cases of serous ovarian cystadenocarcinoma (group 1), in 90% of mucinous ovarian carcinoma (group 2), in 30% of cystadenoma (group 3) and only 10% of the controls expressed Smad-2 (group 4 and 5). 
DISCUSSION
OVARIAN cancer is the fifth most common malignancy in women in the world , yet little is understood about its etiology and less about its pathogenesis. Eighty-seven percent of ovarian cancers are epithelial in origin (34) . The repeated growth and rupture of ovarian epithelium during follicular development and ovulation over the course of a female's reproductive lifetime creates a situation for growth factors to play a critical role in the cycle of continued epithelial proliferation and repair. These growth factors may also promote the growth of neoplastic epithelium. Activin, established as a growth and differentiation factor in a wide variety of tissues and present in abundance in ovarian granulosa cells and follicular fluid, it is a possible candidate for this action.
(34)
In the current study, Activin A levels were found to be increased in the serum of subjects with epithelial serous cystadocarcinoma and mucinous ovarian carcinoma than benign cystadenoma and controls. Activin A secretion correlated significantly with tumor type (P < 0.05); mucinous tumors secreted significantly higher levels of activin A than serous tumors. Mucinous tumors secreted the highest level of activin A. Activin is thought to induce proliferation in epithelial ovarian carcinoma cell lines.
Elevated serum activin A levels in subjects with epithelial ovarian carcinoma suggest that activin may be a factor contributing to tumorigenesis in these patients and that it might have a possible role in ovarian cancer (34) . Increased activin in ovarian tumors may represent an early event that leads to epithelial proliferation.
(35, 36) Thus, Activin A may potentially serve as a tumor marker in the diagnosis and screening of serous and mucinous tumors.
Ovarian cancer cells proliferate in association with high levels of Activin A, which were correlated with advanced stages of the disease, especially with mucinous carcinoma. Activin A is thought not only to stimulate the proliferation of ovarian cancer cells but also has the selective advantage for allowing tumor cell survival because of the positive angiogenic and immunosuppressive effects that allow it to promote tumor growth. In addition, activin A enhances the invasive properties of ovarian cancer cells; most likely through up-regulation of cellular matrix metalloproteinases. Once tumorigenesis is initiated, however, activin signaling may enhance the metastatic process.
(1)
In the present study, the serum levels of Follistatin increased significantly in patients with mucinous and serous ovarian carcinomas than cystadenoma and controls. This increase indicates that the Activin is not bound to its binding protein, follistatin. This keeps the activin free, thus increasing the effect of activin on induction of proliferation of ovarian cancer cells.
Follistatin (FS), an activin binding and neutralizing protein, was found to decrease proliferation in the cell lines producing activin (34) . In patients with advanced stage of tumors and hematological malignancies, free follistatin levels were elevated (37) . Activin signaling is regulated extracellularly by FS whereas a number of intracellular proteins act to modulate cellular responses to these activin signals. It is therefore the balance between activin and all of its modulators, rather than the actions of any one component, that determines the final biological outcome.
(9)
Ovarian cancer cells receive a myriad of signals from molecules present in ascitic fluid or in the tumor microenvironment, and the interpretation of these signals ultimately results in the cellular response (e.g. grow, die, migrate, invade)
(1) . As regards Smad 2 mRNA it was found to be highly expressed in ovarian mucinous carcinoma (90%) and in serous ovarian cystadenocarcinoma (75%). This expression positively correlated with levels of activin A. These data provide a better understanding of the mechanism of action of the activin in the ovarian carcinoma. Similar results were detected in which Smad 2 mRNA levels were increased during 48 h treatment with activin A (50 ng ml(-1)).
(38)
Activin A performs its signal transduction via Smads, which are pivotal intracellular nuclear effectors. Ligand-induced activation of activin A receptors with intrinsic serine/threonine kinase activity trigger phosphorylation of receptor-regulated Smads (R-Smads), whereas Smad2 and Smad3 are phosphorylated by TGF-β, and activin type I receptors, Smad1, Smad5 and Smad8, act downstream of BMP type I receptors. Activated R-Smads form heteromeric complexes with common-partner Smads (Co-Smads), e.g. Smad4, which translocate efficiently to the nucleus, where they regulate, in co-operation with other transcription factors, coactivators and corepressors, the transcription of target genes (39) . It is shown that the Activin/Smad signaling pathway is functional in ovarian cancer cells which most probably causes positive angiogenic and immunosuppressive effects that allow it to promote tumor growth (40) . In addition, Activin A enhances the invasive properties of ovarian cancer cells; most likely through upregulation of cellular matrix metalloproteinases (41) , most probably through perturbation of the Smad pathway (41) . The present study is among the few that evaluated the link between activin A and Smad pathway in ovarian cancer patients, rather than ovarian cell lines, since a significant positive correlation was found between Smad-2 mRNA and activin A. Perturbation of the Activin A/SMAD signaling pathway may result in progression of ovarian tumors through induction by Activin A.
(11) The results of the present study suggest that activin/Smad pathway may contribute to the aggressive behavior of ovarian cancer cells (35) . Several studies (11, 35) are in agreement with the present results. However, these studies were done on cell lines rather than patients.
Levels of uPA were elevated significantly in patients with serous and mucinous ovarian carcinoma than serous cystadenoma than controls, with highest levels in advanced stages of ovarian cancer.
In the present study, uPA concentrations were significantly higher in invasive tumors compared with low malignant potential tumors, which have been recognized as a separate entity, as the clinical course of these tumors is far more favorable when compared with their invasive counterparts. Similarly, uPA levels were higher in patients with metastases as compared with those without metastases.
These findings demonstrate that uPA is associated with the malignant progression of ovarian cancer. The results are consistent with the hypothesis that elevated levels of uPA may contribute to invasiveness and metastasis of ovarian cancer. These observations indicate a role of uPA in tumor progression and angiogenesis, and may be directly involved in cancer cell migration and invasion.
These results are in agreement with several other studies (42, 43) . Hoffmann et al. (44) were also able to demonstrate prognostic relevance of uPA for ovarian cancer. In contrast, van der Burg et al. detected higher average concentrations of uPA in primary ovarian tumors, but due to large variations between tumors in a small number of patients, these higher values were statistically insignificant.
Proteolytic destruction of the basement membrane and tumor surrounding is a prerequisite of invasion and metastasis of tumor cells. In this process, uPA plays an important role because it is involved in the degradation of the components of the extracellular matrix and basement membrane (46) . The serine protease uPA, in concert with its inhibitor PAI-1, promotes tumor cell adhesion, migration, and proliferation, as well as extracellular matrix degradation and, thus, facilitates tumor cell invasion and metastasis.
(32)
Tumor cell invasion is dependent on finely regulated extracellular proteolytic activity, which allows tumor cells to invade the extracellular matrix. Among the proteolytic enzymes involved in this process are PAs, whose expression in cultured cells is regulated by several types of growth factors and cytokines (47) . Invasive tumor cells not only express cell-associated proteases but also secrete anti-proteases, preventing the overdigestion of the extracellular matrix, which leads to loss of cell attachment. The balance between proteolytic activity and inhibition is crucial in the invasive and metastatic event (47) . A positive correlation was found between Activin A and levels of uPA. Thus, enhanced production of uPA was found most probably in response to elevated production of Activin A. Activin A induced the increase of net PA, which might result in strong proteolytic activity in some specific sites, such as areas of cell-to-cell or cell-to-extracellular matrix contacts. For this reason, drugs that manipulate or suppress signal transduction on the PA system in malignant cells offer a potentially new approach to anticancer therapy.
Plasma Bikunin levels were significantly decreased in serous and mucinous ovarian cancer than in cystadenoma and controls. Lowest levels were found in patients with metastasis.
Bikunin is a Kunitz-type protease inhibitor with tumor-suppressive potential in several malignant cell types, acting at the level of tumor invasion and metastasis . Bikunin specifically inhibits expression of uPA mRNA and proteins, the molecular mechanism underlying the tumor-suppressive effect of bikunin remains elusive.
In the present study, bikunin inhibits uPA in ovarian cancer. This is in agreement with other studies, but on cell lines rather than on patients (47,49) . From the present study, it can be hypothesized that low levels of Bikunin in ovarian cancer patients releases the inhibition of expression of uPA thus causing increase in uPA levels. Also, the low levels of bikunin 
Conclusions:
Ovarian cancer has the highest mortality rate of the gynecological malignancies primarily because of the lack of early detection of the disease. The identification of novel signaling pathways involved in ovarian cancer progression is critical to the development of better diagnostics and more efficacious therapeutics.
In summary, the data provided here clearly demonstrate that circulating activin A levels were elevated in a serous and mucinous ovarian carcinoma. Thus, activin A induces the proliferation of both serous and mucinous ovarian carcinoma. Therefore, Activin A may be regarded as both a potential growth factor and a tumor marker is warranted.
The significantly elevated levels of serum follistatin (Activin -binding protein) in ovarian carcinoma indicated that activin is free and this modulated its signal transduction as illustrated by the expression of Smad-2 in 90% of mucinous ovarian carcinoma and in 75% of serous cystadenocarcinoma. We show that the Activin/Smad signaling pathway is functional in ovarian cancer cells which most probably causes positive angiogenic and immunosuppressive effects that allow it to promote tumor growth. Also, evidenced by the present study, it is proposed that Smad-2 increased the levels of uPA which is a proteolytic enzyme that enhances tumor growth and progression as well tumor cell invasion and metastases.
Our data are the first to illustrate that low Bikunin levels were found to be associated with advanced ovarian cancer. It is postulated that Bikunin, a protease inhibitor, up regulated Activin (in the same manner that it up-regulated TGF-beta).These findings point to a novel role for bikunin in regulating the PA system and Activin A-mediated invasion. It is thought that plasma bikunin concentration might be a strong and independent favorable prognostic marker for ovarian cancer.
It can be concluded that bikunin might attenuate Activin A-elicited signaling cascades in ovarian cancer and that this probably provides the mechanism for the suppression of uPA expression. Treatment with bikunin may be beneficial as an adjuvant therapy to delay the appearance of metastatic disease and/or combined with cytotoxic agents to improve treatment efficacy in advanced ovarian cancers. 
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